Astra Pulmicort Respules
Asthma product designated "approvable" by FDA Feb. 11. The NDA (20-929) for the new dosage form of Pulmicort (budesonide) was submitted in November 1997. An advisory committee review of the product had been scheduled in April 1998, but was postponed
You may also be interested in...
AstraZeneca's sales and marketing restructuring should stimulate growth in the company's respiratory drug portfolio, CEO Tom McKillop maintained during an Aug. 3 briefing in London.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011